Characterisation of a New Poor-Risk Sub-Category of Chronic Phase Chronic Myeloid Leukaemia

慢性粒细胞白血病（CML）的靶向治疗的引入导致了许多患者的良好反应。然而，大约30-40%的患者对这种疗法的反应非常差，迫切需要治疗进展来改善这些患者的反应。为了更好地治疗这些低风险患者，我们的目标是，在这个项目中，发展他们的疾病更好的理解，并从这个确定特定的细胞靶点，为未来的药物治疗/联合治疗。

The introduction of targeted therapy for chronic myeloid leukaemia (CML) has resulted in excellent responses for many patients. However, some 30-40% of patients respond very poorly to this therapy and therapeutic advances are urgently needed to improve response in these patients. In order to better treat these poor risk patients we aim, in this project, to develop a greater understanding of their disease, and from this identify specific cellular targets for future drug treatment/combination therapy.